Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India.


Journal

Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250

Informations de publication

Date de publication:
Historique:
received: 26 07 2021
revised: 18 08 2021
accepted: 20 08 2021
pubmed: 1 9 2021
medline: 27 1 2022
entrez: 31 8 2021
Statut: ppublish

Résumé

To identify the profiles and factors associated with progression/regression of ultrasound-derived hepatic steatosis with type 2 diabetes mellitus seen at a tertiary diabetes center in southern India. Participants were individuals with type 2 diabetes mellitus with at least two consecutive ultrasound measurements available. Hepatic steatosis was assessed using high-resolution B-mode ultrasonography. Admittedly ultrasonography has lower sensitivity and specificity, however, it is the only modality available in a routine clinical setting to screen for hepatic steatosis. Progression or regression of hepatic steatosis was assessed after a mean follow-up of 3.0 ± 2.1 years and correlated with clinical and biochemical parameters. A total of 1835 participants with type 2 diabetes mellitus were studied, of whom 88.6% had some form of hepatic steatosis at baseline which included mild steatosis (grade 1) in 982 (53.5%), moderate steatosis (grade 2) in 628 (34.2%) and severe steatosis (grade 3) in 15 (0.8%). Hepatic steatosis progression, regression or no change in grade of hepatic steatosis were seen in 21.5%, 26.6% and 51.9% of participants. Increase in body weight, body mass index, glycated haemoglobin, serum triglycerides and gamma glutamyl transferase were the factors associated with progression of hepatic steatosis, whereas regression showed reduction in body weight, body mass index, fasting plasma glucose and glycated haemoglobin. Among South Indian type 2 diabetes patients with hepatic steatosis, severity of steatosis progressed in 1/3rd while it regressed in 1/4th. These retrospective data need proper ascertainment in controlled studies.

Identifiants

pubmed: 34464909
pii: S1871-4021(21)00281-2
doi: 10.1016/j.dsx.2021.102261
pii:
doi:

Substances chimiques

Biomarkers 0
Blood Glucose 0
Glycated Hemoglobin A 0
hemoglobin A1c protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102261

Informations de copyright

Copyright © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare no conflict of interest.

Auteurs

Nithyanantham Kamalraj (N)

Madras Diabetes Research Foundation, Chennai, India.

Madhanagopal Sathishkumar (M)

Madras Diabetes Research Foundation, Chennai, India.

Mani Arunvignesh (M)

Madras Diabetes Research Foundation, Chennai, India.

Viswanathan Baskar (V)

Madras Diabetes Research Foundation, Chennai, India.

Saravanan Jebarani (S)

Madras Diabetes Research Foundation, Chennai, India.

Anandakumar Amutha (A)

Madras Diabetes Research Foundation, Chennai, India.

Mohan Deepa (M)

Madras Diabetes Research Foundation, Chennai, India.

Coimbatore Subramanyam Shanthi Rani (CS)

Madras Diabetes Research Foundation, Chennai, India.

Sundaramoorthy Chandru (S)

Dr. Mohan's Diabetes Specialties Centre, Chennai, India.

Ranjit Unnikrishnan (R)

Dr. Mohan's Diabetes Specialties Centre, Chennai, India.

Ranjit Mohan Anjana (RM)

Dr. Mohan's Diabetes Specialties Centre, Chennai, India.

Mardavada Harish (M)

Dr. Mohan's Diabetes Specialties Centre, Chennai, India.

Viswanathan Mohan (V)

Dr. Mohan's Diabetes Specialties Centre, Chennai, India. Electronic address: drmohans@diabetes.ind.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH